Calcification and ossification of muscle

M13_CALCIOSSIMUSCLE

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — M61 Hospital discharge: ICD-9 — 7281B\|7281X Hospital discharge: excluded ICD-10 — M61.0, M61.1 Cause of death: ICD-10 — M61 Cause of death: ICD-9 — 7281B\|7281X Cause of death: excluded ICD-10 — M61.0, M61.1 2 out of 7 registries used, show all original rules.	88
4. Check minimum number of events None	88
5. Include endpoints None	88
6. Filter based on genotype QC (FinnGen only)	88

Control definitions (FinnGen only)

Control exclude: M13_SOFTTISSUE

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: M60-M63
Name in latin: Calcificatio et ossificatio musculi

NAME	M13_CALCIOSSIMUSCLE
CONTROL_EXCLUDE	M13_SOFTTISSUE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	M61
HD_ICD_9	7281B\|7281X
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL	M61[0-1]
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	M61
COD_ICD_9	7281B\|7281X
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL	M61[0-1]
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Calcification and ossification of muscle based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	594	264	323
Only index persons	508	233	275
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	53.41	53.62	53.09
Only index persons	52.03	52.67	51.49

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	88	42	46
Unadjusted period prevalence (%)	0.02	0.01	0.02
Median age at first event (years)	52.01	46.69	56.86

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
82: Matched controls
819

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

M61.9

ICD-10 Finland

Calcification and ossification of muscle, unspecified

+∞

36.1

M61.4

ICD-10 Finland

Other calcification of muscle

+∞

17.3

M61.3

ICD-10 Finland

Calcification and ossification of muscles associated with burns

+∞

10.6

M61.5

ICD-10 Finland

Other ossification of muscle

+∞

9.6

M61.2

ICD-10 Finland

Paralytic calcification and ossification of muscle

+∞

9.6

N03AX16

ATC

pregabalin; oral

4.6

8.0

N03AX12

ATC

gabapentin; oral

6.3

7.4

N02AE01

ATC

buprenorphine; parenteral, sublingual, transdermal

6.0

7.2

N02AX02

ATC

tramadol; systemic, rectal

3.6

7.1

184

ZXA00

NOMESCO Finland

Right side

3.7

6.3

120

7281X

ICD-9 Finland

Disorders of muscle, ligament and fascia, Muscular calcification and ossification[CALCIFICATIO ET OSSIFICATIO MUSCULI ALIA]

+∞

6.3

M16.1

ICD-10 Finland

Other primary coxarthrosis

6.0

6.3

T84.0

ICD-10 Finland

Mechanical complication of internal joint prosthesis

16.6

6.1

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3020779) Urea [Moles/volume] in Serum or Plasma

4.67

7.15

5.9

6.0

9.0

11.0

mmol/l

0.25

(3014007) Fractional oxyhemoglobin in Arterial blood

4.79

6.40

11.8

9.2

95.2

92.4

1.26

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

5.18

6.23

10.0

9.5

—

(3005322) IgE [Units/volume] in Serum or Plasma

5.09

5.72

1.5

1.2

268.1

147.2

u/ml

0.25

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

293

2.89

5.59

5.3

3.5

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

3.13

5.02

1.6

1.8

—

(3023368) Bacteria identified in Blood by Culture

176

2.64

4.47

5.9

4.2

—

(3019060) Gas panel - Arterial blood

3.87

4.39

5.1

3.4

—

(3032080) INR in Blood by Coagulation assay

267

2.51

4.34

6.6

8.2

1.3

1.2

inr

—

(3003458) Phosphate [Moles/volume] in Serum or Plasma

3.11

4.25

4.9

4.8

1.1

mmol/l

0.04

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

159

2.59

4.15

3.9

1.9

—

(3007853) Bacteria identified in Skin by Aerobe culture

3.09

4.05

2.8

1.5

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

139

2.62

4.03

2.1

1.6

1.3

1.6

mg/l

0.22

109

(3019069) Monocytes/100 leukocytes in Blood

303

2.39

3.90

6.7

5.0

8.4

8.8

0.41

291

(3006504) Eosinophils/100 leukocytes in Blood

303

2.39

3.90

6.5

4.8

3.2

2.6

0.98

289

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

546

2.98

3.80

8.1

6.7

74.4

80.0

u/l

0.80

508

(3042936) Bacteria identified in Isolate by Culture

2.79

3.79

2.3

1.9

—

(42870588) Differential panel, method unspecified - Blood

207

2.36

3.64

6.7

4.3

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

10.60

3.55

1.2

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

3.46

3.53

8.8

7.3

24.5

23.7

mmol/l

0.35

(3002030) Lymphocytes/100 leukocytes in Blood

315

2.25

3.43

6.6

4.9

27.7

0.00

299

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

9.08

3.31

1.2

1.3

—

(3026008) Bacteria identified in Urine by Culture

185

2.25

3.16

4.6

2.7

—

(3037522) Nuclear Ab [Titer] in Serum

2.77

3.11

1.6

1.4

337.1

402.7

titre

—

(3052851) Hemolysis interference index of Serum or Plasma

4.65

3.09

2.0

3.5

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

263

2.14

3.04

3.7

3.9

22.4

46.9

ng/l

0.95

183

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

142

2.30

2.98

2.0

1.8

2.3

3.2

mg/l

2.06

120

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

3.35

2.92

1.5

1.4

—

(4306422)

7.05

2.91

1.2

1.3

—

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

2.81

2.88

2.7

2.1

2.2

8.6

ug/l

1.66

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

4.23

2.86

1.9

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

122

2.33

2.85

4.0

3.1

18.6

213.3

ng/l

1.25

100

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

5.33

2.79

2.1

—

(40768806) Pleura Pathology biopsy report

8.73

2.78

1.4

2.8

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

6.34

2.74

1.0

2.3

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.57

2.60

1.4

1.8

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

5.76

2.59

1.5

1.4

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.82

2.58

1.7

1.6

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

3.59

2.47

1.4

1.6

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

254

1.96

2.41

2.1

1.8

87.9

92.1

pmol/l

0.30

134

(3013742) Prealbumin [Mass/volume] in Serum or Plasma

2.65

2.32

1.5

2.0

0.2

g/l

0.43

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

4.13

2.30

2.7

1.2

0.2

g/l

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

5.81

2.24

1.4

1.1

—

(3020891) Body temperature

3.56

2.24

9.0

4.3

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

3.91

2.20

1.6

1.1

—

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

3.11

2.14

1.9

2.2

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.38

2.13

1.5

1.8

—

(3007164) IgA [Mass/volume] in Serum or Plasma

114

2.11

2.10

1.2

1.5

2.0

2.8

g/l

0.90

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

3.71

2.10

1.3

1.5

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

5.22

2.10

1.8

1.2

—

(3044640) Blood type and Crossmatch panel - Blood

213

1.88

2.03

4.3

2.0

—

(3000991) Gas panel - Venous blood

2.46

2.02

12.9

6.6

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

2.21

2.01

1.4

1.2

5.7

u/ml

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

3.53

2.01

1.9

1.6

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

3.36

1.92

1.6

1.8

—

(40761535) Cells panel - Urine sediment

2.53

1.86

5.2

3.1

—

(4010399)

2.53

1.86

1.4

1.3

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

2.93

1.84

1.0

1.2

—

(3013512) EKG study

195

1.82

1.78

3.7

—

(3037467) Urinalysis macro (dipstick) panel - Urine

447

1.78

1.77

6.5

3.6

—

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

4.01

1.74

1.0

1.2

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

2.14

1.71

3.9

6.5

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

713

2.34

1.70

28.3

14.9

4.0

mmol/l

0.49

691

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

3.31

1.69

4.0

2.6

239.0

272.3

ug/l

—

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

2.11

1.66

5.1

3.4

236.9

258.7

u/l

0.22

(3013826) Glucose [Moles/volume] in Serum or Plasma

402

1.72

1.66

8.5

4.3

6.6

6.8

mmol/l

0.40

372

(3022145) Colonoscopy Study observation

2.28

1.64

1.2

1.4

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

1.96

1.52

1.5

1.2

40.7

54.6

iu/ml

—

(3045414) Leukocytes [Presence] in Urine

3.25

1.46

2.0

1.5

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

3.25

1.46

2.0

1.6

—

(3028026) IgM [Mass/volume] in Serum or Plasma

2.39

1.45

1.4

1.5

1.0

1.8

g/l

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

680

2.06

1.43

25.2

12.8

29.0

24.6

mg/l

0.44

542

(3027273) Bicarbonate [Moles/volume] in Venous blood

2.53

1.42

5.1

3.2

22.6

24.2

mmol/l

—

(40760892) CBC W Ordered Manual Differential panel - Blood

164

1.73

1.41

3.2

4.6

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

234

1.66

1.40

4.8

2.6

—

(3005719) IgG [Mass/volume] in Serum or Plasma

2.27

1.38

3.6

1.9

10.4

10.2

g/l

—

(3003327) Ova and parasites identified in Stool by Light microscopy

3.05

1.38

3.0

1.4

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

2.48

1.33

2.1

1.5

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

2.88

1.30

1.2

1.5

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

285

1.59

1.27

3.0

2.5

302.6

124.7

ug/l

0.89

257

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

2.73

1.23

1.2

1.5

—

(3021589) Normoblasts [#/volume] in Blood

287

1.57

1.22

9.2

11.1

0.0

e9/l

0.95

237

(3020564) Creatinine [Moles/volume] in Serum or Plasma

740

2.19

1.22

27.6

15.0

78.5

79.9

umol/l

0.09

740

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

424

1.55

1.18

2.6

3.0

—

(3048689) Calprotectin [Mass/mass] in Stool

1.95

1.15

1.3

2.1

74.7

243.1

ug/g

—

(36304419) Bacteria [Presence] in Urine

173

1.62

1.15

4.1

2.5

—

(3000492) Spirometry study

1.99

1.13

2.2

1.5

—

(3019309) Folate [Moles/volume] in Red Blood Cells

123

1.69

1.11

1.8

1.6

824.7

1228.7

nmol/l

1.47

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.22

1.08

1.3

1.7

—

(40758558) Short blood count panel - Blood

167

1.60

1.07

4.5

7.1

—

(3019550) Sodium [Moles/volume] in Serum or Plasma

709

1.88

1.06

29.0

14.9

139.3

139.7

mmol/l

0.61

689

(3003284) Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence

2.35

1.05

1.6

1.7

—

(3019225) pH of Specimen

1.92

0.96

8.1

5.3

—

(36660697) Celiac disease serology panel - Serum

1.97

0.96

1.0

1.2

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

103

1.68

0.96

1.2

1.5

—

(3034860) Kappa light chains.free [Mass/volume] in Serum

2.31

0.95

1.8

2.0

39.9

82.2

mg/l

—

(3047169) Lambda light chains.free [Mass/volume] in Serum or Plasma

2.31

0.95

1.8

2.0

23.2

30.4

mg/l

—

(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum

2.31

0.95

1.8

1.9

—

1.2

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

121

1.61

0.92

1.6

1.8

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

2.00

0.86

4.7

2.5

1.2

1.6

—

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

0.00

0.80

0.0

1.3

—

200.7

—

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

1.69

0.79

1.2

4.9

1.9

102.7

ug/l

—

(3017446) Testosterone [Moles/volume] in Serum or Plasma

1.73

0.79

2.2

2.3

14.2

13.8

nmol/l

0.03

(3009508) Creatinine [Moles/volume] in Urine

197

1.45

0.78

3.8

2.9

6.9

7.9

mmol/l

0.61

165

(3011397) Hemoglobin [Presence] in Urine by Test strip

135

1.52

0.77

4.3

3.0

—

(40768804) Tissue Pathology biopsy report

264

1.40

0.74

2.3

2.1

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

2.06

0.74

7.8

4.5

24.4

25.7

mmol/l

—

(3008898) HLA-B27 [Presence]

2.06

0.74

1.2

1.1

—

(3012544) pH of Venous blood

1.64

0.74

4.6

2.8

—

(3002256) Pathology report gross observation

1.60

0.71

1.4

1.3

—

(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

751

1.72

0.70

12.9

9.2

26.3

26.5

u/l

0.06

725

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.68

0.68

1.3

1.5

—

(3041096) Erythrocytes [Presence] in Urine by Automated

196

0.66

0.67

3.2

3.1

—

(3022313) Gas panel - Capillary blood

1.77

0.65

7.8

4.0

—

(1761868) Lipid panel - Serum or Plasma

285

0.74

0.55

2.2

2.8

—

(3025941) Bacteria identified in Stool by Culture

1.58

0.54

1.7

1.3

—

(3018095) Leukocytes [#/volume] in Urine

238

1.33

0.54

5.1

3.0

360.4

79.3

e6/l

0.43

169

(3002385) Erythrocyte distribution width [Ratio]

578

1.32

0.50

24.5

16.8

14.0

13.8

0.35

569

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.45

0.49

1.4

1.5

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

269

0.76

0.48

4.7

3.4

—

(40768797) Stomach Pathology biopsy report

1.46

0.47

1.4

1.3

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.44

0.43

1.4

1.6

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.41

0.0

1.3

—

(40761511) CBC panel - Blood by Automated count

733

1.40

0.41

21.2

12.7

—

(3012501) Base excess in Blood by calculation

0.00

0.41

0.0

3.3

—

2.5

—

(3013290) Carbon dioxide [Partial pressure] in Blood

0.00

0.41

0.0

3.3

—

4.8

—

(3027315) Oxygen [Partial pressure] in Blood

0.00

0.41

0.0

3.3

—

8.4

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.40

0.0

1.4

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

1.45

0.40

1.2

1.3

—

(3003694) ABO and Rh group [Type] in Blood

184

1.26

0.35

1.3

—

(3024731) MCV [Entitic volume]

783

1.43

0.33

34.1

19.1

91.7

91.2

0.49

772

(3010813) Leukocytes [#/volume] in Blood

783

1.43

0.33

35.0

19.2

7.0

6.7

e9/l

0.64

761

(3026361) Erythrocytes [#/volume] in Blood

783

1.43

0.33

35.0

19.1

4.4

4.5

e12/l

1.33

761

(3035941) MCH [Entitic mass]

783

1.43

0.33

34.0

19.0

30.6

30.4

0.28

772

(3000963) Hemoglobin [Mass/volume] in Blood

784

1.42

0.33

34.3

19.2

132.6

136.5

g/l

1.32

774

(3007461) Platelets [#/volume] in Blood

781

1.47

0.33

34.9

19.1

249.4

245.2

e9/l

0.23

762

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.36

0.29

1.3

1.6

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.25

0.28

2.1

4.0

—

(4035726)

1.23

0.27

1.8

1.4

—

(3044889) 12 lead EKG panel

484

1.18

0.27

4.7

3.7

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

1.20

0.22

4.0

5.1

25.0

24.9

mmol/l

—

(3034770) Mitochondria Ab [Titer] in Serum

0.00

0.21

0.0

1.2

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

0.21

0.0

1.2

—

(3007566) Smooth muscle Ab [Titer] in Serum

0.00

0.21

0.0

1.1

—

(3028271) Lactate [Moles/volume] in Capillary blood

0.00

0.21

0.0

2.8

—

1.4

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.7

—

(40760847) Basement membrane Ab [Titer] in Serum by Immunofluorescence

0.00

0.21

0.0

1.2

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

0.21

0.0

1.0

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

657

1.15

0.17

22.2

12.8

88.6

80.8

ml/min/173m2

2.05

532

(21494755) Public health laboratory ask at order entry panel

0.74

0.16

1.3

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

212

0.87

0.16

3.2

4.3

18.8

20.1

—

103

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.77

0.15

1.3

1.4

—

(3012516) Albumin [Mass/volume] in Urine

190

1.14

0.14

4.2

3.0

74.6

413.9

mg/l

—

125

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

1.14

0.09

1.3

1.4

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.12

0.08

1.9

1.7

—

(3009542) Hematocrit [Volume Fraction] of Blood

649

1.07

0.05

24.8

13.6

40.1

0.01

461

(3020682) Albumin/Creatinine [Ratio] in Urine

203

1.05

0.01

5.0

3.9

11.1

9.3

mg/mmol

—

127

(3004789) Transferrin [Mass/volume] in Serum or Plasma

101

0.99

0.00

2.7

2.1

2.4

g/l

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.02

0.00

1.9

—

(3000081) cloZAPine [Moles/volume] in Serum or Plasma

0.00

0.0

24.9

—

1570.2

—

(3041423) Sjogrens syndrome-A extractable nuclear 60kD Ab [Units/volume] in Serum

0.00

0.0

1.4

—

(40760848) Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.1

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.0

1.4

—

(3027953) Aldolase [Enzymatic activity/volume] in Serum or Plasma

0.00

0.0

1.0

—

6.1

—

(3041067) Sjogrens syndrome-A extractable nuclear 52kD Ab [Units/volume] in Serum

0.00

0.0

1.4

—

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

0.00

0.0

1.1

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

0.00

0.0

1.2

—

(3032699) Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3019897) Erythrocyte distribution width [Ratio] by Automated count

0.00

0.0

1.0

—

13.4

—

(3011648) Oxygen content in Venous blood

0.00

0.0

1.0

—

10.7

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.00

0.0

1.4

—

(3021236) Streptolysin O Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

337.4

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.2

—

(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma

0.00

0.0

1.9

—

16.2

—

(3008832) Norclozapine [Moles/volume] in Serum or Plasma

0.00

0.0

12.8

—

801.1

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.85

0.00

1.0

1.3

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.4

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.0

—

(3000494) Fungus identified in Specimen by Culture

0.95

0.00

1.5

1.4

—

(40766800) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood

0.00

0.0

1.0

—

(40764127) Haemophilus influenzae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3022806) Fractional oxyhemoglobin in Capillary blood

0.00

0.0

2.4

—

90.5

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.0

1.4

—

(3015183) Erythrocyte sedimentation rate

0.00

0.0

1.7

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

0.0

4.0

—

2.5

—

(3023511) Choriogonadotropin [Units/volume] in Urine

0.00

0.0

1.0

—

(3013727) Leukocytes other/100 leukocytes in Blood

0.00

0.0

5.0

—

47.0

—

(3045683) HLA typing for celiac disease panel - Blood or Tissue

0.00

0.0

1.0

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

0.0

1.1

—

(3037875) Bordetella parapertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3017569) Oxygen content in Arterial blood

0.00

0.0

11.3

—

(3038026) Centromere Ab [Units/volume] in Serum

0.00

0.0

1.4

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

0.00

0.0

1.0

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.97

0.00

1.3

1.6

—

(3044242) Glucose [Moles/volume] in Arterial blood

0.00

0.0

15.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint M13_CALCIOSSIMUSCLE and mortality.

Females

No data

Males

Parameter	HR [95% CI]	p-value
M13_CALCIOSSIMUSCLE	1.461 [1.02, 2.09]	0.037
Birth year	0.993 [0.98, 1.0]	0.108

During the follow-up period (1.1.1998 — 31.12.2019), 64 out of 217 males with M13_CALCIOSSIMUSCLE died.

Mortality risk

Mortality risk for people of age

years, who have M13_CALCIOSSIMUSCLE.

N-year risk	Females	Males
1	No data	0.288%
5	No data	2.012%
10	No data	5.072%
15	No data	9.751%
20	No data	16.361%

Relationships between endpoints

↥

Index endpoint: M13_CALCIOSSIMUSCLE – Calcification and ossification of muscle

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Calcification and ossification of muscle

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints